Management of immune-mediated uveitis

BioDrugs

Volumn 13, Issue 1, 2000, Pages 9-20

  Smith, Justine R ^a   Rosenbaum, James T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM CARBONATE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOMODULATING AGENT; INDOMETACIN; KETOROLAC; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; VITAMIN D;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; META ANALYSIS; PRIORITY JOURNAL; REVIEW; STEROID THERAPY; TERATOGENICITY; UVEITIS;

EID: 0033963391     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200013010-00002     Document Type: Review

References (76)

1. 1. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987: 103: 234-5
2. 2. Rosenbaum JT, Holland GN. Uveitis and the Tower of Babel. Arch Ophthalmol 1996; 114: 604-5
3. 3. Linssen A, Rothova A, Valkenberg HA, et al. The lifetime cumulative incidence of acute anterior uveitis in a normal pop ulation and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Invest Ophthalmol Vis Sci 1991; 32: 2568-78
4. 4. Rothova A, Suttorp-van Schulten MS, Frit Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammation. Br J Ophthalmol 1996; 80: 332-6
5. 5. Rodriguez A, Calonge M, Pedroza-Seres M, et al. Referral patterns of uveitis in a tertiary eye care centre. Arch Ophthalmol 1996; 114: 593-9
6. 6. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997; 115: 61-4
7. 7. Salinas-Carmona MC, Nussenblatt RB, Gery I. Experimental autoimmune uveitis in the athymic nude rat. Eur J Immunol 1982; 12: 480-4
8. 8. Smith JR, Hart PH, Parish CR, et al. Experimental melanin-induced uveitis in the Fischer 344 rat is inhibited by anti-CD4 monoclonal antibody, but not by mannose-6-phosphate. Clin Exp Immunol 1999; 115: 64-71
9. 9. McMenamin PG, Crewe J. Endotoxin-induced uveitis. Kinetics and phenotype of the inflammatory cell infiltrate and the response of the resident tissue macrophages and dendritic cells in the iris and ciliary body. Invest Ophthalmol Vis Sci 1995; 36: 1949-59
10. 10. Wakefield D, McCluskey P, Palladinetti P. Distribution of lymphocytes and cell adhesion molecules in iris biopsy specimens from patients with uveitis. Arch Ophthalmol 1992; 110: 121-5
11. 11. Ohta K, Norose K, Wang X, et al. Apoptosis-related fas antigen on memory T cells in aqueous humor of uveitis patients. Curr Eye Res 1996; 15: 299-306
12. 12. La Heij, Kuijpers RWAM, Baarsma SG, et al. Adhesion molecules in iris biopsy specimens from patients with uveitis. Br J Ophthalmol 1998; 82: 432-7
13. 13. Muhaya M, Calder V, Towler HMA, et al. Characterization of T cells and cytokines in the aqueous humour (AH) in patients with Fuchs' heterochromic cyclitis (FHC) and idiopathic anterior uveitis (IAU). Clin Exp Immunol 1998; 111: 123-8
14. 14. Woods AC. ACTH and cortisone in ocular disease. Am J Ophthalmol 1950; 33: 1325
15. 15. Anglade E, Whitcup SM. The diagnosis and management of uveitis. Drugs 1995; 49: 213-23
16. 16. Dick AD, Azim M, Forrester JV. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 1997; 81: 1107-12
17. 17. Wong VG. Immunosuppressive therapy of ocular inflammatory diseases. Arch Ophthalmol 1969; 81: 628-37
18. 18. Wong VG, Hersh EM. Methotrexate in therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol 1965; 69: 279-93
19. 19. Lazar M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969; 67: 383-7
20. 20. Mathews JD, Crawford BA, Bignell JL, et al. Azathioprine in active chronic iridocyclitis. Br J Ophthalmol 1969; 53: 327-30
21. 21. Buckley CE 3rd, Gills, Jr JP. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med 1969; 124: 29-35
22. 22. Nussenblatt RB, Palestine AG, Rook AH, et al. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983; II (8344): 235-8
23. 23. Tamesis RR, Rodriguez A, Christen WG, et al. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology 1996; 103: 768-75
24. 24. McCombs CC, DeShazo RD. Immune system disorders. In: Speight TM, Holford NHG, editors. Avery's drug treatment. Auckland: Adis International, 1997: 1295-345
25. 25. Leibowitz HM, Kupferman A. Bioavailability and therapeutic effectiveness of topically administered corticosteroids. Trans Am Acad Ophthalmol Otolaryngol 1975; 79: OP-78-88
26. 26. Dunne JA, Travers JP. Double-blind clinical trial of topical steroids in anterior uveitis. Br J Ophthalmol 1979: 63: 762-7
27. 27. Jennings T, Rusin MM, Tessler HH, et al. Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol 1988; 32: 385-91
28. 28. Riordan-Eva P, Lightman S. Orbital floor steroid injections in the treatment of uveitis. Eye 1994; 8: 66-9
29. 29. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995; 120: 55-64
30. 30. Yoshikawa K, Kotare S, Ichiishi A, et al. Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macula edema. Jpn J Ophthalmol 1995; 39: 71-6
31. 31. Freeman WR, Green RL, Smith RE. Echographic localization of corticosteroids after periocular injection. Arch Ophthalmol 1987; 103: 281-8
32. 32. Foster CS, Alter G, DeBarge LR, et al. Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996; 122: 171-82
33. 33. Loteprednol Etabonate CS Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol 1999; 127: 537-44
34. 34. Whitcup SM, Ferris FL. New corticosteroids for the treatment of ocular inflammation. Am J Ophthalmol 1999; 127: 597-9
35. 35. Weijtens O, Van Der Sluijs FA, Schoemaker RC, et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol 1997; 123: 358-63
36. 36. O'Day DM, McKenna TJ, Elliott JH. Ocular corticosteroid therapy: systemic hormonal effects. Trans Am Acad Ophthalmol Otolaryngol 1975; 79: OP-71-7
37. 37. Hill JC. Immunosuppression in corneal transplantation. Eye 1995; 9: 247-53
38. 38. The Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997; 115: 1545-52
39. 39. Stanbury RM, Graham EM. Systemic corticosteroid therapy -side effects and their management. Br J Ophthalmol 1998; 82: 704-8
40. 40. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991; 35: 369-85
41. 41. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992; 99: 1419-23
42. 42. Holz FG, Krastel H, Breithart A, et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992; 1: 142-4
43. 43. Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998; 133: 266-8
44. 44. Dev S, McCallum R, Jaffe GJ. Methotrexate therapy for sarcoid-associated panuveitis. Ophthalmology 1999; 106: 111-8
45. 45. Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK 1976; 87: 499-511
46. 46. Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978; 96: 247-51
47. 47. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's disease. N Engl J Med 1990; 322: 281-5
48. 48. Oniki S, Kurakazu K, Kawata K. Immunosuppressive therapy of Behcet's disease with cyclophosphamide. Jpn J Ophthalmol 1976; 20: 32-40
49. 49. Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol 1994; 21: 123-5
50. 50. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040
51. 51. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991; 112: 138-46
52. 52. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989; 1 (8647): 1093-6
53. 53. Palestine AG, Austin HA 3rd, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986; 314: 1293-8
54. 54. Bielory L, Holland C, Gascon P, et al. Uveitis, cutaneous and neurosarcoid: treatment with low-dose cyclosporine A. Transplant Proc 1988; 20 (S4): 144-8
55. 55. Towler HM, Lightman SL, Forrester JV. Low-dose cyclosporin therapy of ocular inflammation: preliminary report of a long-term follow-up study. J Autoimmun 1992; 5 (SA); 259-64
56. 56. Cohen E, Raz J, Maltzir G, et al. Low-dose cyclosporine A in uveitis: a long term follow-up. Ocul Immunol Inflamm 1993; 1: 195-201
57. 57. Whitcup SM, Salvo, Jr EC, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol 1994; 118: 39-45
58. 58. Diaz-Llopis M, Cervera M, Menezo JL. Cyclosporin A treatment of Behcet's disease: a long-term study. Curr Eye Res 1990; 9 (S): 17-23
59. 59. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating, chronic, noninfectious uveitis. Ophthalmology 1996; 103: 365-74
60. 60. Nguyen QD, Foster CS. Saving the vision of children with juvenile chronic rheumatoid arthritis-associated uveitis. JAMA 1998; 280: 1133-4
61. 61. Sand BB, Krogh E. Topical indomethacin, a prostaglandin inhibitor, in acute anterior uveitis. A controlled clinical trial of non-steroid versus steroid anti-inflammatory treatment. Acta Ophthalmol 1991; 69: 145-8
62. 62. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991; 112: 514-9
63. 63. Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology 1991; 98: 944-51
64. 64. Pascalis L, Pia G, Aresu G, et al. Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun 1993; 6: 467-80
65. 65. Ramadan AM, Nussenblatt RB, de Smet MD. Long-term follow-up of patients with chronic uveitis affecting the posterior pole treated with combination cyclosporine and ketoconazole. Ophthalmology 1997; 104: 706-11
66. 66. Thurau SR, Wildner G, Reiter C, et al. Treatment of endogenous uveitis with anti-CD4 monoclonal antibody: first report. German J Ophthalmol 1994; 3: 409-13
67. 67. Isaacs JD, Hale G, Waldmann H, et al. Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. Br J Ophthalmol 1995; 79: 1054-5
68. 68. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33-8
69. 69. Charpentier B, Thervet E. Placebo-controlled study of humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplanlation. Transplant Proc 1998; 30: 1331-2
70. 70. Dick AD, Cheng YF, Liversidge J, et al. Immunomodulation of experimental autoimmune uveoretinitis: a model of tolerance induction with retinal antigens. Eye 1994; 8: 52-9
71. 71. Nussenblatt RB, Gery I, Weiner HL, et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol 1997; 123: 583-92
72. 72. Kotter I, Eckstein AK, Stubiger N, et al. Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 1998; 82: 488-94
73. 73. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86
74. 74. Rosenbaum JT, George RK, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 1999; 127: 545-9
75. 75. Cheng CK, Berger AS, Pearson PA, et al. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest Ophthalmol Vis Sci 1995; 445-53
76. 76. Jaffe GJ, Yang CS, Wang XC, et al. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology 1998; 105: 46-56